glp-1 obesity drugs pipeline What is the for future medications for obesity? GLP-1 Pipeline Update: November 2024

Concern was initially raised by the findings of the SUSTAIN-6 CVOT that suggested the risk of DR complications was elevated in patients using semaglutide compared with placebo (3.0% vs 1.8%, P = .02)

This led to higher levels of cyclin D1, a protein crucial for promoting cell proliferation, suggesting a potential pathway for GLP-1RAs to increase risk for PDAC in humans

Be mindful of serving sizes and avoid eating directly from packages to prevent overeating

Improved HbA1c: GLP-1 drugs consistently reduce HbA1c an important long-term marker of diabetes control often by 11.5%, depending on the agent and dose

And without the continued downward trajectory that motivated continued use, exploring alternatives with different mechanisms becomes an appealing strategy to break through stalled progress